Optimizing Intensive Chemotherapy Management in Secondary AML Through Academic Community Collaboration

home / insights / optimizing-intensive-chemotherapy-management-in-secondary-aml-through-academic-community

Margaret Kasner, MD, and Christian Fidler, MD, discuss how effective management of secondary acute myeloid leukemia (AML) in community settings requires early diagnosis, accurate risk stratification, timely referrals, personalized treatment approaches, robust supportive care, and close collaboration with academic centers to ensure optimal patient outcomes.

2 KOLs are featured in this series.

EP. 1: Implementing Updates to AML Classification Guidelines

Margaret T. Kasner, MD;Christian Fidler, MD
October 18th 2024

Panelists discuss how secondary acute myeloid leukemia (AML) presents unique challenges in diagnosis, classification, and treatment due to its complex pathogenesis and evolving classification criteria.

2 KOLs are featured in this series.

EP. 2: Treatment Goals in Secondary AML

Margaret T. Kasner, MD;Christian Fidler, MD
October 18th 2024

Panelists discuss how secondary acute myeloid leukemia (AML) generally carries a poorer prognosis compared to de novo AML, necessitating careful consideration of treatment goals and open communication with patients about their outlook.